NYSE American - Delayed Quote USD

Chromocell Therapeutics Corporation (CHRO)

Compare
0.7299 +0.0344 (+4.95%)
At close: October 21 at 3:59 PM EDT
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
--
199.9340
Operating Expense
8,868.6090
6,862.2840
2,318.1590
838.9960
1,553.8010
Operating Income
-8,868.6090
-6,862.2840
-2,318.1590
-838.9960
-1,353.8670
Net Non Operating Interest Income Expense
-929.7520
-518.5090
-140.4300
-0.2530
-1.6760
Other Income Expense
--
--
--
243.8620
694.9590
Pretax Income
-9,794.8340
-7,380.7930
-2,458.5890
-595.3870
-660.5840
Net Income Common Stockholders
-9,794.8340
-7,380.7930
-2,458.5890
-595.3870
-660.5840
Diluted NI Available to Com Stockholders
-9,794.8340
-7,380.7930
-2,458.5890
-595.3870
-660.5840
Basic EPS
-1.68
-1.28
-0.26
-0.10
-0.07
Diluted EPS
-1.68
-1.28
-0.26
-0.10
-0.07
Basic Average Shares
5,823.1660
5,767.5250
9,286.9280
5,767.5250
9,286.9280
Diluted Average Shares
5,823.1660
5,767.5250
9,286.9280
5,767.5250
9,286.9280
Total Operating Income as Reported
-8,868.6090
-6,862.2840
-2,318.1590
-838.9960
-1,353.8670
Total Expenses
8,868.6090
6,862.2840
2,318.1590
838.9960
1,553.8010
Net Income from Continuing & Discontinued Operation
-9,794.8340
-7,380.7930
-2,458.5890
-595.3870
-660.5840
Normalized Income
-9,794.8340
-7,380.7930
-2,458.5890
-839.2490
-1,355.5430
Interest Expense
929.7520
518.5090
140.4300
0.2530
1.6760
Net Interest Income
-929.7520
-518.5090
-140.4300
-0.2530
-1.6760
EBIT
-8,865.0820
-6,862.2840
-2,318.1590
-595.1340
-658.9080
EBITDA
-8,865.0820
-6,862.2840
-2,318.1590
-595.1340
-658.9080
Net Income from Continuing Operation Net Minority Interest
-9,794.8340
-7,380.7930
-2,458.5890
-595.3870
-660.5840
Total Unusual Items Excluding Goodwill
--
--
--
243.8620
694.9590
Total Unusual Items
--
--
--
243.8620
694.9590
Normalized EBITDA
-8,865.0820
-6,862.2840
-2,318.1590
-838.9960
-1,353.8670
12/31/2020 - 2/16/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers